FY24 Update and FY25 Guidance
A: 78 Apollo Drive, Rosedale, Auckland 0632, New Zealand
PO Box: 302-533 North Harbour, Auckland 0751, New
Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
11 December 2024
Market Announcement
For immediate release
FY24 update and FY25 guidance
Guidance for the year ending 31 December 2024 was previously updated on 30
th
October. AOF stated that
revenue was expected in the range $75m to $80m with EBITDA targeted at around $2.5m. AoFrio Limited
(AOF) remains on track to achieve this EBITDA target, and revenue is now expected to be at the top end of
that range at around $79m, which represents a growth rate of approximately 18.7%.
The SaaS solution for Food Retail customers continues to progress well. Three proof-of-concept trials have
been completed with customers across different geographies and commercial discussions have progressed
to point that initial orders are now anticipated in early 2025. AOF expects revenue from this solution to
include a recurring SaaS component.
Based on the approved budget for 2025, AOF expects revenue for the 2025 year in the range of $85m to
$95m, a 14% increase over 2024 at the midpoint of the range. EBITDA guidance for 2025 is targeting a
range of $3.5m to $4.0m. As always, macroeconomic conditions may impact this guidance.
*EBITDA (i.e., Earnings before interest, taxation, depreciation, amortisation, and impairment) is a non-GAAP
earnings figure that equity analysts tend to focus on for comparable company performance analysis. AoFrio
considers it a valuable financial indicator because it avoids the distortions caused by differences in
amortisation and impairment policies. Contact
Ends
Contact
Greg Balla Howard Milliner
Chief Executive Officer Chief Financial Officer
Phone + 64 21938601 +64 275870455
AO189
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS2025-01-12
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 13 January 2025 NEW YEAR LETTER TO INVESTORS AFT putting building blocks in…”
- AFT — AFT Pharmaceuticals Limited: AFT reports record sales and invests for growth2024-11-20
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 21 NOVEMBER 2024 FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2024 AFT reports record s…”
- AFT — AFT Pharmaceuticals Limited: AFT trading update2024-10-31
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com on its full year guidance when it releases its interim FY25 results on Thursday 21 November 2…”